MAPT and Alzheimer disease: Cdk5 activation is responsible for abnormalities of the amyloid, tau, and neurofilament proteins in AD, implying that GCN5 may be critically involved in the pathogenesis of AD, but additional experimental evidence is needed [14, 15, 16].